Business Context and Reporting Period
Telomir Pharmaceuticals, Inc. (TELO), an emerging growth company incorporated in Florida, filed this Form 8-K on July 22, 2025, reporting events occurring on July 18, 2025. The company is listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing reports a specific capital raising event rather than periodic financial results. Key metrics from the transaction include:
- Shares Sold: 1,100,000 shares of common stock.
- Average Price: $2.6045 per share.
- Gross Proceeds: Approximately $2.9 million.
- Transaction Type: Block sales to institutional investors via an at-the-market equity offering facility.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific offering.
Material Changes
The primary material change is the increase in outstanding common stock and cash proceeds resulting from the July 18, 2025 offering. The shares were sold at a premium to the prior day's closing price. No other material changes to operations or financial condition are detailed in this report.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the equity offering. The transaction was facilitated through Rodman & Renshaw via the StockBlock platform and did not include any warrants.
Investor Verification Checklist
- Verify the exact net proceeds after deducting fees and expenses, as only gross proceeds ($2.9 million) are stated.
- Confirm the updated total number of outstanding shares following the issuance of 1,100,000 new shares.
- Review the company's most recent 10-Q or 10-K for current cash balances and burn rate to assess the impact of the $2.9 million infusion on liquidity.
- Check for any subsequent filings regarding the use of proceeds or additional at-the-market offerings.